OverviewSuggest Edit

Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. This breakthrough platform addresses currently undruggable targets, and offers an alternative to existing drug modalities for a wide range of disease conditions.

TypePublic
HQCambridge, US
Websitemodernatx.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Dec 2018)760(+12%)
Job Openings55
Revenue (FY, 2018)$135.1 M(-34%)
Share Price (Oct 2019)$14.5 (+3%)

Key People/Management at Moderna Therapeutics

Stephane Bancel

Stephane Bancel

CEO
Stephen Hoge

Stephen Hoge

M.D., President
Juan Andres

Juan Andres

Chief Technical Operations and Quality Officer
Marcello Damiani

Marcello Damiani

Chief Digital Officer
Annie Seibold Drapeau

Annie Seibold Drapeau

Chief Human Resources Officer
Lori Henderson

Lori Henderson

J.D., General Counsel and Corporate Secretary
Show more

Moderna Therapeutics Office Locations

Moderna Therapeutics has offices in Cambridge, Norwood, Chicago, Huntington and in 1 other location
Cambridge, US (HQ)
320 Bent St
Cambridge, US
200 Technology Square
Cambridge, US
NE47, 500 Technology Square
Norwood, US
Norwood, MA, USA
Huddinge, SE
Hälsovägen 7-9
Show all (7)

Moderna Therapeutics Financials and Metrics

Moderna Therapeutics Revenue

Moderna Therapeutics's revenue was reported to be $135.07 m in FY, 2018
USD

Revenue (Q2, 2019)

13.1m

Net income (Q2, 2019)

(135.1m)

EBIT (Q2, 2019)

(143.9m)

Market capitalization (17-Oct-2019)

4.8b

Closing stock price (17-Oct-2019)

14.5

Cash (30-Jun-2019)

151.6m
Moderna Therapeutics's current market capitalization is $4.8 b.
Annual
USDFY, 2016FY, 2017FY, 2018

Revenue

108.4m205.8m135.1m

Revenue growth, %

90%

General and administrative expense

57.5m64.7m94.3m

R&D expense

274.7m410.5m454.1m
Quarterly
USDQ1, 2019Q2, 2019

Revenue

16.0m13.1m

General and administrative expense

27.3m28.5m

R&D expense

130.6m128.5m

Operating expense total

157.9m157.0m
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

50.1m134.9m658.4m

Accounts Receivable

13.4m11.9m11.7m

Prepaid Expenses

15.5m12.8m

Current Assets

1.1b783.2m1.6b
Quarterly
USDQ3, 2018Q1, 2019Q2, 2019

Cash

167.1m502.9m151.6m

Accounts Receivable

9.8m5.6m3.5m

Prepaid Expenses

33.4m

Current Assets

1.1b1.1b1.1b
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(216.2m)(255.9m)(384.7m)

Depreciation and Amortization

17.6m21.6m24.9m

Accounts Payable

6.0m(12.8m)15.0m

Cash From Operating Activities

66.7m(331.5m)(330.9m)
Quarterly
USDQ3, 2017Q3, 2018Q1, 2019Q2, 2019

Net Income

(243.3m)(218.0m)(132.7m)(267.7m)

Depreciation and Amortization

58.4m43.6m7.3m14.8m

Accounts Payable

718.0k(9.9m)1.7m(1.5m)

Cash From Operating Activities

(239.8m)(228.6m)(143.9m)(256.1m)
USDY, 2019

Financial Leverage

1.3 x
Show all financial metrics

Moderna Therapeutics Operating Metrics

Moderna Therapeutics's Clinical Programs was reported to be 10 in Q3, 2018.
Y, 2015May, 2017Q3, 2018

Clinical Programs

10

Drugs in Development

92

Patent Applications

250

Patents Issued

100
Show all operating metrics

Moderna Therapeutics Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Brizo
Moderna AB
Moderna Securities
ModernaTX

Moderna Therapeutics Revenue Breakdown

Embed Graph

Moderna Therapeutics revenue breakdown by business segment: 14.0% from Grant revenue, 14.6% from Collaboration revenue from affiliate and 71.4% from Collaboration revenue

Moderna Therapeutics Online and Social Media Presence

Embed Graph

Moderna Therapeutics News and Updates

Moderna Therapeutics, a biotech unicorn valued at more than $7.5 billion, could be gearing up for an IPO as early as this winter

Biotech unicorn Moderna Therapeutics, which is valued at more than $7.5 billion, may file for an initial public offering as early as this winter, according to STAT news.  The company has reportedly hired banks including Goldman Sachs, JPMorgan, and Morgan Stanley to help it with its debut on Wall …

Moderna Therapeutics racks up $500 mln

Cambridge, Massachusetts-based Moderna Therapeutics, a developer of messenger RNA therapeutics and vaccines, has raised $500 million in funding. The investors include a subsidiary of the Abu Dhabi Investment Authority, EDBI, Sequoia Capital China, Fidelity Management & Research Company, Pictet, …

Moderna Therapeutics Blogs

Novel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of Classic Galactosemia

This pre-clinical study shows that systemic administration of mRNA encoding the enzyme GALT reduced toxic metabolites in mouse models of the rare genetic disease, Classic Galactosemia. This study supports the potential of mRNA therapy to target proteins that cannot be treated by traditional enzyme …

Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency

This pre-clinical study shows that repeat dosing of mRNA encoding ARG1 delivered via lipid nanoparticles was able to treat mouse models of arginase deficiency and supports the potential of mRNA therapeutics to treat rare metabolic disorders. Publication Date:  Friday, August 9, 2019 Is Featured:  …

Moderna to Host R&D Day on September 12, 2019

Moderna to Host R&D Day on September 12, 2019 Content Import Thu, 08/29/2019 - 08:00 Moderna to Host R&D Day on September 12, 2019 August 29, 2019 at 8:00 AM EDT This release is a backfill from a News Wire General CAMBRIDGE, M…

Moderna to Present at Upcoming Investor Conferences

Moderna to Present at Upcoming Investor Conferences william.meady@… Tue, 08/27/2019 - 08:00 Moderna to Present at Upcoming Investor Conferences August 27, 2019 at 8:00 AM EDT This release is a backfill from a News Wire General CAMBRID…

Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893

Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893 Content Import Mon, 08/19/2019 - 16:01 Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893 August 19, 2019 at 4:01 PM EDT This release is a backfill from a News Wire …

Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results

Phase 2 Personalized Cancer Vaccine (mRNA-4157) study initiated, with first patient consented Phase 1 CMV vaccine (mRNA-1647) study fully enrolled Four new Phase 1 studies have begun, two in immuno-oncology and two in infectious diseases Vertex Pharmaceuticals extended the companies’ CF research
Show more

Moderna Therapeutics Frequently Asked Questions

  • Who are Moderna Therapeutics key executives?

    Moderna Therapeutics's key executives are Stephane Bancel, Stephen Hoge and Juan Andres.

  • How many employees does Moderna Therapeutics have?

    Moderna Therapeutics has 760 employees.

  • What is Moderna Therapeutics revenue?

    Latest Moderna Therapeutics annual revenue is $135.1 m.

  • What is Moderna Therapeutics revenue per employee?

    Latest Moderna Therapeutics revenue per employee is $177.7 k.

  • Who are Moderna Therapeutics competitors?

    Competitors of Moderna Therapeutics include Pernix Therapeutics, Celyad and CureVac.

  • Where is Moderna Therapeutics headquarters?

    Moderna Therapeutics headquarters is located at 320 Bent St, Cambridge.

  • Where are Moderna Therapeutics offices?

    Moderna Therapeutics has offices in Cambridge, Norwood, Chicago, Huntington and in 1 other location.

  • How many offices does Moderna Therapeutics have?

    Moderna Therapeutics has 7 offices.